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A B S T R A C T
In Down syndrome (DS), epilepsy is frequent in all age classes and is recognized as a signiﬁcant
cause of additional handicap and morbidity. Longer life expectancy has led to the recognition of the
high incidence of both Alzheimer’s disease and seizures in elderly persons with DS. Neuropatholog-
ical markers of AD are found in all DS brains and clinical symptoms of AD become apparent by the
age of 60 years and above in over 50% of DS subjects. Following preliminary description of myoclonic
seizures and/or myoclonic epilepsy in isolated cases or small series, we wish to report the diagnostic
criteria, treatment and prognosis of a speciﬁc and recognizable form of epilepsy associated with AD
in a larger group of middle-aged to elderly DS patients. This markedly under-recognized entity may
indeed concern an already large and steadily increasing number of patients. We reviewed all medical
records of patients with DS referred to our centers (Centre Saint Paul-Gastaut, Marseille; Epilepsy Unit,
Montpellier University Hospital; Department of Neurology, Hospital General de Asturias, Oviedo) since
1995. DS had been diagnosed in all at birth, and all presented with the typical morphological changes
associatedwithDS.Weselectedall cases (18) referredasadultswithnewonsetofmyoclonic jerks (MJ) and/
or behavioral or cognitive deterioration (CD).
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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journal homepage: www.e lsev ier .com/ locate /yse izIn Down syndrome (DS), epilepsy is frequent in all age
classes and is recognized as a signiﬁcant cause of additional
handicap and morbidity.1–5 Longer life expectancy has led to
the recognition of the high incidence of both Alzheimer’s
disease (AD) and seizures in elderly persons with DS.6
Neuropathological markers of AD are found in all DS brains7
and clinical symptoms of AD become apparent by the age of 60
years and above in over 50% of DS subjects.8 Although nearly all
elderly DS patients develop seizures,9,10 little attention has been
paid to the clinical characteristic of epilepsy in this special
category. Following preliminary description of myoclonic
seizures and/or myoclonic epilepsy in isolated cases or small
series,11–16 we wish to report the diagnostic criteria, treatment
and prognosis of a speciﬁc and recognizable form of epilepsy
associated with AD in a larger group of middle-aged to elderly
DS patients. This markedly under-recognized entity may indeed
concern an already large and steadily increasing number of
patients.* Corresponding author. Tel.: +33 491 170 750; fax: +33 491 170 791.
E-mail address: piergen@aol.com (P. Genton).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.04.0081. Patients and methods
We reviewed all medical records of patients with DS referred to
our centers (Centre Saint Paul-Gastaut, Marseille; Epilepsy Unit,
Montpellier University Hospital; Department of Neurology, Hospi-
tal General de Asturias, Oviedo) since 1995. DS had been diagnosed
in all at birth, and all presented with the typical morphological
changes associatedwith DS.We selected all cases referred as adults
with new onset of myoclonic jerks (MJ) and/or behavioral or
cognitive deterioration (CD). We did not use a standardized test to
evaluate CD, but had to rely on the observations of caregivers, and
carefully inspected the notes collected in the institutions where
most patients lived. We also collected all medical ﬁles, EEG
tracings, video–EEG recordings and neuroimaging data concerning
these patients. All patients were seen several times. Because of
variable general health and social conditions, there was no regular
or scheduled uptake of the patients who were followed according
to the requests of their caretakers.
2. Results
Eighteen observations (6 M, 12 F) fulﬁlled our criteria (Table 1).
The cause of referral was the onset of myoclonic jerks, oftenvier Ltd. All rights reserved.
Table 1
Birth Death Sex First
contact
Caregiver Copathologies Onset (years) MR/CT EEG Video–
EEG
Dementia Jerks GTCS Age at
death
1 1932 72years F 1993 Family Phlebitis
Cataract
59 59 63 72 Normal (CT) Generalized SW PPR
2 yrs before death
Yes
2 1948 M 2004 Institution Phlebitis
hypothyroidism






3 1947 F 2004 Institution Mitral insufﬁciency
left eye blindness
B hepatitis




4 1966 M 1995 Institution Hypothyroidism
focal epilepsy at
age 14, in remission
36 38 36 Normal (CT) Diffuse slowing;
generalized SSW
No
5 1948 F 1981 Institution Retinal rupture,
seizures at age 33
(in remission)




6 1948 F 2004 Institution Hypothyroidism
Hyperuricemia





7 1965 F 2005 Family Hypothyroidism 36 39 40 ND Generalized SW and
polySW PPR
Yes
8 1955 F 2006 Institution 46 47 45 ND Diffuse slowing
generalized SW
Yes





10 1957 F 2007 Institution Hypothyroidism 47 50 50 ND Diffuse slowing photic
driving without PPR
No
11 1965 F 2008 Institution Hypothyroidism 38 42 – ND Diffuse slowing No
















15 1957 49years M 2001 Family 44 44 49 ND Diffuse slowing No
16 1947 M 1998 Family 51 51 52 ND Diffuse slowing No
17 1953 50years F 2002 Family 49 48 48 50 Diffuse atrophy
(CT)
NA No
18 1955 F 2008 Family Cataracts
Heart defect
Hypothyroidism






CT: computer tomography; MRI: magnetic resonance imaging; ND: not done; PPR: photoparoxysmal response; SW: spike-waves.
R. De Simone et al. / Seizure 19 (2010) 383–389384associated with falls, in nine (pat. 1–3, 6, 7, 10, 14–16), a
generalized tonic–clonic seizure (GTCS) in seven (pat. 5, 8, 9, 12, 13,
17, 18), while one patient (pat. 4) was already followed for
preexisting epilepsy, and another patient was referred for
suspected epilepsy in a context of CD, and MJ appeared only
during follow-up (pat. 11).
All patients showed signs of cognitive and behavioral deterio-
ration with progressive loss of autonomy. Onset of cognitive
deterioration occurred at a mean age of 48.2 years (median 49, SD
6.5, range 36–59). All had MJ with mean onset at 50 years (median
51, SD 6.3, range 38–59). Thirteen had GTCS: for these, average
onset was at 49.8 years (median 50, SD 6.98, range 36–63); the
earliest GTCS had occurred at age 36 in patient 4, who had
experienced nocturnal focal seizures earlier in life.
Patients were ﬁrst seen at various stages of their condition:
patient 5 had been evaluated at age 33 for seizures 19 years prior to
the onset of CD, and patient 12 was seen for CD 5 years before the
onset of MJ. Among the other 16 patients, ﬁve were seen within 1
year of onset of cognitive deterioration (pat. 6, 14–17), although
the precise onset of CDwas difﬁcult to ascertain in pat. 14–17; four
between 1 and 3 years after onset (patients 1, 9, 10, 18); seven, 4 or
more year after the onset (patients 2, 3, 4, 7, 8, 11, 13). Two patients
had prior epilepsy, and among the 16 others, 11 were ﬁrst seen
within 1 year after the onset of MJ or GTCS.
Cognitive deterioration was present in all. It was marked
clinically by loss of interests and social interactions, forgetfulness,disorientation in space and time. In 14 it was the initial symptom,
alone or associated with myoclonus (six patients) or CGTS (one
patient). In all cases, it was progressive with a ﬁnal bedridden
situation. All patients exhibited some type of behavioral disorder
after the onset of CD. Four patients died, all were bedridden with
severe dementia:
 Pat. 1, at age 72, 13 years after the onset of CD and of MJ.
 Pat. 14, 15 and 17 died at age 61, 49 and 50, respectively 6, 5 and
2 years after the onset of symptoms, which occurred in close
succession, over less than a year (although CD may have
preceded the occurrence of seizures in these three patients, but
this could not be adequately assessed from our ﬁles; they had
been referred at a late stage of their condition).
All patients exhibitedMJ, which were prominent at or soon after
awakening inall in the early stagesof their condition, except inpat. 5
and17, inwhomthedatawerenot reliable, and inpat. 6, inwhomMJ
occurred somewhat later in the morning. Myoclonic jerks appeared
sometimes as asymmetrical to clinical observers and were always
associated with generalized discharges on the EEG when docu-
mented. At a later stage, with progression of dementia, MJ occurred
diffusely over the daytime and appeared as parcellar and less easily
recognizable. Falls due to massive MJ were the main reason for
referral in six patients. MJ occurred simultaneously or apparently
simultaneously with the ﬁrst symptoms of CD in seven (with
[(Fig._1)TD$FIG]
Fig. 1. Patient 1: Drawing abilities at age 46 (a) and 2 years after seizure onset, at age
62 (b), showing a marked deterioration.
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years in four, within 3–6 years in seven.
GTCS were reported in 14 patients, including in recently
evaluated pat. 10, who had her ﬁrst GTCS a fewweeks after her ﬁrst
evaluation for MJ in 2007. Patient 4 had had a series of GTCS 20
years before the onset of CD andMJ, and had been considered to be
in remission of earlier epilepsy. The onset of GTCS had apparently
preceded CD in 2 patients, was simultaneous with CD in two, and
occurred 1–4 years after CD in the others.
EEGwas performed in 17 patients (no documentation in patient
17) according to the 10–20 international system with one or more
channels for EMG polygraphy and showed diffuse slowing in 13
patients, generalized spike-wave (SW) and polySW in 10,
generalized and parcellar myoclonus (seven patients); in pat. 18,
no MJ were recorded on the video–EEG in spite of positive history,
possibly because the patient had been treated with LEV 1000 mg/d
prior to the ﬁrst EEG recording. Video–EEG documentation of MJ
was obtained in seven cases. In patient 9, EEG transiently showed
also a massive diffused slowing concomitant with valproate-
induced encephalopathy, after the resolution of which there was
still diffuse irregular slowing and numerous isolated interictal
spikes and SW. Six patients showed a photoparoxysmal response
(PPR) on intermittent photic stimulation (IPS) consisting in brief
myoclonic jerks, although no patient exhibited signs of photosen-
sitivity in daily life. In patient 13, PPR was evident a 11–21 Hz,
appearing only 9 years after the start of CD. Successive EEG
recordings showed that background activity tended to remain
normal during the ﬁrst years following the onset of dementia, and
that sharp interictal and ictal changes increased progressively over
the years, parallel to the slowing of background. Neuroimagingwas
performed in nine patients, showing in eight mild to moderate
diffuse cortical and subcortical cerebral atrophy.
Valproate (VPA) was used at 500–1000 mg/d, alone (six
patients) or with levetiracetam (LEV) 1000 mg/d (ﬁve patients),
topiramate (TPM) 100 mg/d (one patient), or lamotrigine (LTG)
50 mg/d (one patient). A clear suppression of seizures was seen in
ﬁve cases (two with VPA alone). LEV was used alone at the dosage
of 1000 mg/d (two patients) with a documented good effect on MJ
(but recurrence of GTCS in one), or with VPA (ﬁve patients) or LTG
100 mg/d (one patient) or piracetam (PIR) (one patient) with a
documented good effect in four cases. In patient 12, the association
of VPA 1000 mg/d and LEV 1000 mg/d appeared efﬁcacious on MJ,
whereas VPA and LEV used separatelywere inefﬁcacious. TPM, LTG
and PIR were used only in combination with LEV, VPA, or
phenobarbital (PB) (ﬁve patients) with a documented good effect
in three cases. In addition to anticonvulsants, nine patients
received either antidepressants or neuroleptics or both. Hypothy-
roidism was compensated in all those affected. All associated
conditions were considered stable.
The two following cases illustrate the progression of this
condition, which was slow in patient 1 and rapid in patient 8.
Patient 1: This woman, born in 1932was referred in 1993, at age
61 years, because of repeated falls in the morning after awakening.
BilateralMJ, evidentwhile the patientwas lying in her bed or in the
early morning, had been increasingly noted for the past year. She
livedwith two unmarried siblings, and had neither a family history
of epilepsy nor other organic complications of DS. At age of 59 she
had phlebitis, at age of 60 she was operated for cataracts. A
progressive cognitive decline had occurred over the past 2 years,
particularly involving short-termmemory and praxis, as shown by
the deterioration of hermarked drawing abilities (Fig. 1a and b). At
awakening from nocturnal sleep, the EEG shows normal back-
ground with generalized SW and polySW associated with MJ
(Fig. 2). She was given PIR 25 g/d and VPA 500 mg/d, but MJ,
involving both arms and legs, slowly increased. A ﬁrst GTCS
occurred in 1995. VPAwas increased to 1000 mg/d. Repeated sleepEEG showed increased slowing of background. Clobazam and LEV
were added to VPA and PIR, resulting in abatement of myoclonus.
In 2000, a video–EEG showed erratic myoclonus, more evident in
the early morning after awakening, asynchronous and predomi-
nant in the upper limbs, infrequently associated with generalized
isolated spikes. IPS evoked MJ, while it had been negative in 1993.
GTCS persisted (one to several per year). Cognitive impairment and
dependency progressed, and the patient, bedridden for her last 2
years, died of pneumonia inMarch, 2005, 14 years after the onset of
cognitive decline and 12 years after the onset of MJ.
Patient 8: This woman, born in 1955, had no family history of
epilepsy and no signiﬁcant personal history. In 2000, she had an
isolated generalized tonic–clonic seizure, and was given pheno-
barbital 100 mg/d. The same year, her caregivers noted progressive
memory problems, confusion, and spatial and temporal disorien-
tation. During 2002, massive myoclonus appeared, mainly in the
earlymorning, after awakening. In 2004 shewas totally dependent,
unable to walk and to recognize her family. The patient was given
LEV 1000 mg/d with a good effect on myoclonus. In 2006, the EEG
showed diffuse slowing, generalized SW associated with axial
myoclonus and parcellar myoclonus without apparent EEG
anomalies (Fig. 3), as well as increased subclinical SW discharges
during ILS. In 2006, after several falls, VPA 1500 mg/dwas added. A
CTwas performed in 2004 and showedmild diffuse subcortical and
cortical cerebral atrophy. The patient is now bedridden.
3. Discussion
In our centers, no DS patient aged more than 50 years was
referred for epilepsy or cognitive deteriorationwho did not present
[(Fig._2)TD$FIG]
Fig. 2. Patient 1: Polygraphic EEG performed at awakening 2 years after the onset of myoclonic jerks and before the onset of GTCS; (a and b) no slowing of background activity,
generalized spike- and polyspike-and-wave complexes associatedwith bilateral myoclonic jerks; (c) enlargement of (b) showing the relationship between EEG discharge and
jerk. Recording speed: 15 mm/s.
[(Fig._3)TD$FIG]
Fig. 3. Patient 8: Polygraphic EEG performed in the latemorning 6 years after the onset of cognitive decline andGTCS, and 4 years after the onset ofmyoclonic jerks. The patient
was already severely demented with permanent myoclonus. Note the marked slowing of the background activity and frequent diffuse bursts of spike and wave complexes,
generally coupled withmyoclonic jerks; also note the presence of unilateral myoclonias that are not associated with EEG activities (EMG1: right deltoid; EMG2: left deltoid).
Recording speed: 15 mm/s.
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patient exhibited new onset of focal seizures. Although recruit-
ment bias is possible, this entity appears as the typical, perhaps
obligate presentation of middle-aged or elderly DS subjects who
experience the symptoms of AD.
The ﬁrst clinical description of late-onsetmyoclonus in patients
with DS appeared in abstract form.17 In a series of 14 patients, the
EEG recordings showed no speciﬁc change. The author mentioned
the use of VPA, without specifying the results. In 1994, Genton and
Paglia11 described the case of a 61-year-old patient (our pat. 1). In
1995 Li et al.12 described a 51-year-oldmanwith a ﬁrst GTCS at age
50, followed by myoclonic jerks occurring either at or soon after
awakening. In 2001 Mo˝ller et al.13 described a 55-year-old patient
with a ﬁrst generalized myoclonic–tonic seizure; myoclonic jerksof the upper extremities had begun 3 years earlier, usually in the
morning; they improved on VPA and TPM. The EEG showed
generalized continuous slowing as well as generalized SW,
occasionally associated with generalized MJ occurring 180–
250 ms after the onset of the polyspike component. Our group
recently described four further cases of the syndrome (pat. 2, 5, 12,
13).15,16 We have thus now collected 12 more cases.
Veall1 showed an increased prevalence of epilepsy in DS with
increasing age (1.9% under 20 years and 12.2% over 55 years) in
1654 patients with DS, and underlined the absence of evident
causes of epilepsy. This rate becomes greater after a long-term
monitoring of patients: in a study covering 12 years of observation,
36.8% of DS patients had epilepsy.18 The ethnic background is
important: Eastern studies, from Japan19 and China,20 showed a
R. De Simone et al. / Seizure 19 (2010) 383–389 387low rate of epilepsy in DS patients. Veall1 suggested a bimodal
distribution in the age of onset of seizures, while Pueschel,5 in 405
patients with DS, aged from 0.5 to 45 years, reported a triphasic
distribution of epilepsy with peaks in infancy, early adulthood, and
in patients over 50–55 years. In 1994, McVicker et al.21 reported a
prevalence of 9.4% in a population of 191 patients with DS,
increasing with age, being particularly high (46%) in those over the
age of 50; the age of distribution of epilepsy showed an early peak
in the third decade; a second peak was observed in the ﬁfth and
sixth decades. The clinical features of epilepsy in DS are variable,
depending on age: infantile spasms,4,19 childhood-onset myoclon-
ic epilepsies, reﬂex epilepsy22,23 and anecdotal forms like benign
myoclonic epilepsy.24 All types of seizures are represented but
GTCS seem to be the most common.3
The cause of higher prevalence of epilepsy in DS is not clear:
structural abnormalities and biochemical disorders of CNS may be
responsible, but copathologies, e.g. cardiovascular diseases and
infections, may play a part. The brain of DS patients is small and
globular, with a relative paucity of cells in the cortex. Kemper25
observed a lower neural density and abnormal neuronal distribu-
tion, in particular in cortical layers 2 and 4. Dysgenesis of dendritic
spines in the form of longer and thinner necks has been reported,26
and linked to epileptogenesis. Scott27 observed hyperexcitable
membrane properties in cultured dorsal root ganglion neurons
from fetuseswith DS. A defect in serotonin uptake in platelets of DS
patients and a defect in cholinergic transmission sensible to age in
particular regions as the superior colliculus and substantia nigra
were reported28,29 A signiﬁcant role may be played by a defect in a
gene coding for a subunit of glutamatergic receptor, the GluR5,
coded in distal arm of chromosome 21, a critical region for DS.30
More recently, Thiel and Fowkes31 have suggested a nutritional
factor of seizure development in DS. The triple chromosome 21
results in overexpression of many enzymes that are encoded on it,
with consequent over-consumption of enzymatic substrates and
overproduction of metabolic end-products. For example, the
overexpression of the SOD-1 gene decreases the levels of hydrogen
peroxide and causes metabolic changes, with impairment of
neurotransmitter synthesis and possible alterations of membrane
oxidative mechanisms. The lack of many nutritional factors like
vitamins, oligoelements and amino acids, and the high amount of
other substances, like cysteine and phenylalanine, typical of DS
patients, could also play a major role in epileptogenesis.32 Finally,
epilepsy can result from amix of several factors that could drive to
the ﬁnal pathway of hyper-excitability, i.e. modiﬁcations of
cellular membranes, structural modiﬁcation, and alteration of
inhibitory transmission.
Several authors have noted that late-onset epilepsy was
associated with the neuropathological changes of AD.9,10 The high
frequency of myoclonus in DS, especially in elderly patients,33 has
been explained by the frequent and early onset of dementia in DS.
Nevertheless, myoclonus is also a symptom of AD. In a population
of 83 AD cases, Hauser et al.34 found a cumulative risk of
myoclonus of 12% by 10 years after onset of AD symptoms, and 17%
by 16 years. Therefore, myoclonus is an accepted symptom of AD,
with a physiologic basis that is not clearly understood: Wilkins
et al.35 suggested a cortical origin, thus linking seizures (also
present in AD patients with a 10-fold increase of risk) and
myoclonus.
DS patients over the age of 40 show neuropathological changes
characteristic of AD, including neuroﬁbrillary tangles, neuritic
plaques, and neuron cell loss.36 In an extensive survey of autopsy
data for adults with DS, Schweber7 found that brain pathology of
AD was universal in those aged 37 and over. While increases of
diffuse plaques are not associated with dementia and neuronal
degenerations, increases in the numbers of neuritic plaques,
containing substantial amounts of ﬁbrillised Ab peptides, areobserved in adults with DS predominantly after 50 years of age and
are associated with neuronal degeneration and loss of function.37
The clinical manifestations of AD in DS could be closely associated
with the development of these neuritic plaques. A further
consequence of increasing longevity of DS patients has been the
increasing number of reports of AD cases.Most studies have shown
that the average age at onset of dementia is between 50 and 55
years, with a range from 38 to 70 years.9,38 Lai and Williams9
identiﬁed in 96 patients with DS and dementia three phases of
clinical deterioration. Seizures, mostly tonic–clonic, emerged in
84% of the patients. The dementia associated with DS generally
follows a rapidly progressive course: death typically occurs within
3–5 years from the onset. In a recent study,8 a total of 92
hospitalized persons with DS were followed from 1985 to 2000.
Eighteen (21%) patients developed dementia during follow-up,
with a median age of onset 55.5 years (range 45–74). Dementia
was associated with neuropathological features of Alzheimer’s
disease, and correlated with neocortical neuroﬁbrillary tangle
densities. At the age of 60 years and above, more than 50% of
patients still alive had clinical evidence of dementia. The presence
of great rates of AD in DS has been explained by a dose effect of the
amyloidal precursor protein (APP).39 APP on chromosome 21
appears not to be up-regulated in adult DS brains by microarray or
QPCR analysis, but numerous other genes functionally linked to
APP processing are dysregulated: these are involved in develop-
ment (notably notch signaling and Dlx family genes), lipid
transport, and cellular proliferation.40
Chromosome 21 contains several genes that have been
implicated in neurodegenerative mechanisms. These include Cu/
Zn superoxide dismutase (SOD-1), Ets-2 transcription factors,
Down syndrome Critical Region 1 (DSCR1) stress-inducible factor,
and the amyloid precursor protein (APP).41 A key component of the
senile plaques is the amyloid beta-peptidewhich is generated from
the amyloid precursor protein (APP) by sequential action of beta-
secretases (BACE1 and BACE2) and gamma-secretase.While BACE1
maps to chromosome 11, APP and BACE2 are located on
chromosome 21.42 Dual speciﬁcity tyrosine phosphorylation-
regulated kinase 1A (DYRK1A) gene on chromosome 21 is
overexpressed in DS, resulting in increased amounts of phos-
pho-Ser-202-Tau and phospho-Ser-404-Tau.43
Overexpression of APP in the obligate region for DS is associated
with abundant Abeta plaques and tangles consistent with Braak
stages V–VI. Intraneuronal Abeta in DS appears to trigger a
pathological cascade leading to oxidative stress and a neurode-
generation typical of AD. There are suggestions that an increase in
subcellular processing of APP and factors related tomembrane APP
cleavage favor the secretion of Abeta with age in DS. A misbalance
between SOD-1 and glutathione perioxidase activity inDS has been
linked to free radical generation. Ets-2 and DSCR1 overexpression
in DS has been linked to cell degeneration. Age-related accumula-
tion of somatic DNA mutations in both DS and AD contribute to
oxidative stress that exacerbates the imbalance in gene expression.
This leads to enhanced Abeta deposition and further neuronal
vulnerability.41 Factors that inﬂuence the formation of deposits of
beta-amyloid in neuritic plaques and neuroﬁbrillary tangles, such
as apolipoprotein E (APOE) e4 allele, oestrogen deﬁciency, high
levels of Ab1–42 peptides, elevated expression of BACE2, and
valine polymorphism of prion protein gene, are important in the
pathogenesis of AD, and in earlier onset of dementia in DS.44 DS
patients with APOE e4 allele had signiﬁcantly higher risk of
developing AD (HR = 1.8, 95% CI: 1.12–2.79), had an earlier onset of
AD (55.0 years vs. 57.0 years; p = 0.0027) and a more rapid
progression to death comparedwith participantswith e3 allele (4.2
years vs. 5.4 years, respectively, p = 0.048).45 Conversely, factors
that decrease the formation of Ab, such as the APOE e2 allele or
atypical karyotypes (as translocations, partial trisomies or
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dose, are associated with lower mortality and reduced risk of
dementia.46
This entity was diagnosed after a certain delay, because of the
patients’ background and social position. Indeed, the earliest
referrals of our patients were due to their families, soon after the
onset of MJ or GTCS. However, CD and behavioral disorders have a
very gradual, progressive onset in these patients, and failed to be
recognized early because of the background disability. MJ may not
be perceived until they lead to falls, or the patient may be referred
only after the ﬁrst GTCS.
In all descriptions, dementia appears as regularly progressive,
as witnessed by caregivers and/or shown by neuropsychological
assessment. It is described as the ﬁrst symptom of the syn-
drome9,10,11,47; precise assessment of cognitive deterioration may
be difﬁcult in a mentally handicapped population. Speciﬁc
neuropsychological testing48 is available, but we did not employ
these in our patients, relying instead on clinical observations
performed in the family or by caregivers in institutions. In most
cases, we were able to date with fair precision the onset of the
cognitive decline.
Massive, bilateral MJ, sometimes leading to falls, are the major
initial feature of the epilepsy and were present in all. They occur
initially and characteristically at awakening. Whenever it was
possible to record them on polygraphic video–EEG, they were
associated with generalized SW discharges. In a later stage, they
occur more diffusely over the day, and there are also erratic,
fragmentary myoclonias that are not associated with evident
changes on the EEG except overall slowing. Photoparoxysmal EEG
responses were found in ﬁve patients, usually at a late stage of the
evolution. GTCS were not present in all, but they may occur at a
later stage and had been seen in all the patients whowere followed
until death. In our series, three had a GTCS as the ﬁrst recorded
epileptic event. Treatment may prevent myoclonus and seizures,
and VPA and LEV, alone or associated, appear to be the most
efﬁcacious. However, not unexpectedly, symptomatic treatment
did not inﬂuence the progressive course of the condition.
The characteristics of epilepsy associated with ageing and
Alzheimer-type dementia in DS appear unequivocal, and justify the
term of ‘‘senile myoclonic epilepsy’’, as this condition mimics, at
onset, the classical syndrome of ‘‘juvenile’’ myoclonic epilepsy.49
Typically, this truly progressive myoclonic epilepsy follows a
sequence of dementia, awakening MJ and GTCS and progresses
towards erratic myoclonus, full dependency and death within
years. The EEG is not very informative at onset, and sleep EEG
polygraphy may be necessary to record the signiﬁcant features at
awakening. The EEG progressively deteriorates with slowing of
background and increase of paroxysmal changes. Senile myoclonic
epilepsy apparently results from the combination of a background
of DS and the progressive changes associated with AD.
Down syndrome represents 1–3 per 1000 births,50 or 37.6 per
10,000 births in Paris,51 i.e. at least 1000 new cases per year in
France (present population around 63 millions, with around
800,000 births per year). Given (1) the markedly increased life
expectancy of DS patients, (2) the fact that all ageing DS patients
are exposed to AD, and (3) that all those presenting with clinical
signs of dementia are very likely to develop this type of epilepsy,
senile myoclonic epilepsy will probably soon become a common
epilepsy syndrome. It is already frequent, although still under-
recognized. Early recognition and therapy may avoid traumatic
falls and GTCS. The particular context opens wide possibilities for
studies on the prevention of both AD and epilepsy. As compara-
tively little attention has been devoted to the characterization of
epilepsy and myoclonus in non-DS AD patients, the scope of senile
myoclonic epilepsy might indeed be enlarged to a much wider
population at risk. At present, senile myoclonic epilepsy probablyalready represents the commonest form of progressive myoclonic
epilepsy.
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